Amarin Ducks Securities Action Over Vascepa Denial
A New Jersey federal judge has dismissed a securities class action against biopharmaceuticals maker Amarin Corp. PLC that claimed it artificially inflated its stock price before a U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article